| Autor: |
Amrane K; From the Departments of Oncology., le Pennec R; Nuclear Medicine., Schick U; Radiotherapy, University Hospital of Brest., Metges JP; From the Departments of Oncology., Abgral R |
| Jazyk: |
angličtina |
| Zdroj: |
Clinical nuclear medicine [Clin Nucl Med] 2020 Sep; Vol. 45 (9), pp. 707-708. |
| DOI: |
10.1097/RLU.0000000000003190 |
| Abstrakt: |
Triplet chemotherapy (FOLFOXIRI) + bevacizumab regimen is indicated as first-line treatment of BRAF-mutated metastatic colorectal cancer (mCRC). Nevertheless, its proven therapeutic efficacy in clinical trials was solely based on partial morphologic responses assessed by CT. To date, only 1 case of complete response assessed by FDG PET/CT was reported in literature in BRAF-mutated mCRC, but treated with doublet chemotherapy (FOLFIRI) + cetuximab regimen. We report a complete metabolic response assessed by FDG PET/CT, maintained over time (13 months) in a 60-year-old woman with BRAF-mutated mCRC treated by FOLFOXIRI-bevacizumab. This also confirms that FDG PET/CT is emerging as a useful approach for therapeutic assessment of targeted drugs in mCRC. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
